From Deference To Scrutiny: Standard of Care, Informed Consent And Regulatory Classification Of Stem Cell Therapies
Aleena Mary Joseph
20 May 2026 8:00 PM IST
Indian medical law has long operated within a framework of judicial deference. For nearly seven decades, one test has defined the medical negligence standard across common law jurisdictions, articulated by McNair J. in Bolam v. Friern Hospital Management Committee [1957] 1 WLR 582, a doctor is not negligent if she acts in accordance with a practice accepted as proper by a responsible body of medical men skilled in that particular art. The logic was deferential by design. Courts were not medical experts; clinicians were. Standards of care, on this view, were properly determined by the profession itself, not by judges. The Bolam standard adopted by the Supreme Court in Jacob Mathew v. State of Punjab (2005) 2005 INSC 334 held that a practitioner who acts in accordance with a responsible body of medical opinion fulfils their duty of care. The practical consequence was significant. Professional custom became effectively self-validating. A practitioner sued for negligence needed only to find a colleague willing to say she had done what any reasonable practitioner in her position would do. Independent judicial scrutiny of whether the underlying practice was actually safe, evidence-based, or rational was largely foreclosed. The standard of care was anchored in practice, not in science. The structural effect was a near-complete insulation of clinical custom from independent judicial examination. If a defendant practitioner could identify any body of respectable opinion supporting her conduct, the negligence action ordinarily failed. The only meaningful check that the opinion be "responsible" was itself measured by reference to whether other practitioners held it, generating a circularity that courts were institutionally reluctant to interrogate.
It is against this backdrop that Yash Charitable Trust v. Union of India (2026) 2026 INSC 96 decided by Justices J.B. Pardiwala and R. Mahadevan on January 30, 2026, acquires its doctrinal significance. The case arose from a writ petition challenging the proliferation of commercial stem cell clinics offering therapies for autism spectrum disorder (ASD)- therapies that lacked established scientific evidence of efficacy and were administered without regulatory approval as drugs. The Court's response advances Indian medical jurisprudence on three interconnected fronts: it formally integrates the Bolitho v. City & Hackney Health Authority [1997] UKHL 46 refinement into the negligence standard; it definitively classifies stem cell preparations for unapproved indications as drugs under the Drugs and Cosmetics Act, 1940, stripping away the procedure characterisation that had shielded commercial operators from regulatory accountability; and it reconceptualises informed consent under Article 21 of the Constitution as requiring disclosure grounded in an honest assessment of evidence, not merely procedural disclosure of known risks. Each of these moves is analytically significant. Together, they represent a structural shift from deference to scrutiny in Indian medical law.
I. The Negligence Standard: Closing the Bolam Loophole
The Bolam formulation is well understood. Under Jacob Mathew, a practitioner is not negligent if she acts in the manner of an ordinary competent practitioner in her field. Courts were deliberately kept at arm's length from substantive clinical evaluation; the standard of care was determined by practice, not by courts, and courts accepted that arrangement.
English law addressed the limits of this arrangement in Bolitho v. City & Hackney Health Authority [1998] AC 232. Lord Browne-Wilkinson held that a body of professional opinion, to qualify as legally "responsible," must be capable of withstanding logical analysis, particularly when weighing risks against benefits. The refinement was deliberately narrow in scope; he accepted that cases where professional consensus fails logical scrutiny would be rare, and was careful not to invite courts to substitute their own clinical judgment. But the doctrinal point was real. Bolitho removed Bolam's immunity in cases where professional practice exists without an evidential foundation.
In Yash Charitable Trust, the distinction was determinative. Clinics offering stem cell therapies for autism spectrum disorder did not act in isolation; a significant number of practitioners offered substantially similar treatments. Under a pure Bolam analysis, that convergence might have constituted the "responsible body" needed to defeat liability. The Court's adoption of the Bolitho refinement cuts through it. The relevant question was not whether practitioners offered such therapies, but whether the practice had a logical basis in established scientific evidence. The Court's finding of a dearth of such evidence is precisely the factual condition that, under Bolitho, prevents professional convergence from qualifying as a legally responsible standard.
The Court also invoked Article 51A(h), the Fundamental Duty to cultivate scientific temper, as a constitutional yardstick for evaluating professional opinion. This is creative, but contestable. Article 51A, addressed to citizens, is generally considered non-justiciable, and applies to institutions only through strained inference. The Bolitho refinement, read alongside the Article 21 right to health as elaborated in Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996) 1996 INSC 621, provides a more doctrinally secure foundation for the Court's insistence on evidential rationality. Whether Article 51A(h) survives as an independent constitutional mandate for clinical epistemology is a question that will need to be resolved in subsequent litigation.
II. Drug Classification: Closing the "Procedure" Escape Route
Drugs are all substances used for the treatment, mitigation or prevention of any disease in human beings as stated in the Drugs and Cosmetics Act, 1940, section 3(b). Rule 2(zd) of the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules) also defines a new drug as any biological substance (including cell-based products) which has not been approved, or used for an indication before. The ICMR-DBT Guidelines for Stem Cell Research and Therapy 2017 had already carved out the distinction, minimally manipulated cells for homologous applications are not drugs; those that are more than minimally manipulated or used in non-homologous applications would be subject to the demands of drug registration, including those of Phase I, II and III clinical trials before commercial administration.
In practice, clinics providing stem cell therapies for ASD had characterised their work as "procedures" or "treatment protocols", a framing designed to bypass the CDSCO licensing regime entirely. Yash Charitable Trust forecloses that argument. The Court's classification of such preparations as new drugs triggers three immediate legal consequences. First, their administration without CDSCO approval is subject to criminal sanction under Section 27 of the D&C Act. Second, the pharmacovigilance and adverse event-reporting obligations that apply to drug manufacturers apply equally to the administering establishments. Third and most significant for the consent analysis, the doctrinal space for a "consented unlicensed use" theory collapses. A patient cannot validly consent to the unlicensed commercial administration of a drug any more than she can consent to the supply of an unregistered pharmaceutical; the licensing requirement is not a procedural technicality but a substantive precondition to lawful clinical administration.
The judgment must be read carefully to avoid overreach. The 2017 Guidelines had already permitted certain stem cell applications within registered clinical trial settings. The Court's decision isn't that stem cell research is prohibited, it's that administering stem cells outside of the trial is illegal. It is important to note that the judgment differentiates between the clinical trial pathway (permissible, regulated) and the outside of the clinical trial pathway (impermissible).
III. Informed Consent: The Epistemic Dimension
The established consent doctrine in Indian law derives from Samira Kohli v. Dr. Prabha Manchanda (2008) 2008 INSC 56. Valid consent must be obtained after disclosure of the nature of the treatment, the risks and complications of the treatment, and the options available to the patient. The paradigm case was the extension of procedure beyond what a patient had agreed to, or had consented to. The framework was built around a practitioner withholding information she possessed. The question raised in Yash Charitable Trust is different in kind. The deficiency was not that practitioners withheld known information. It was that the information they communicated, i.e., representations of therapeutic benefit for ASD, was not supported by any credible scientific evidence. This is not a disclosure problem in the traditional sense; it is an epistemic problem. The informational content of the consent was false, not merely incomplete. The patient was not told less than the practitioner knew; she was told something the practitioner had no evidential basis to assert.
The Court's Article 21 framework addresses this directly. Autonomous decision-making, which Article 21 protects, cannot be meaningfully exercised based on representations that misstate the evidential status of a therapy. Consenting to something presented as an established treatment, when the practitioner knew or should have known it was at best experimental, is not the same as consenting to experimental participation. The patient did not bargain for what she received; she was deceived about the category of intervention she was agreeing to.
The Court's conclusion that such consent is "null and void ab initio" must not be read as a general proposition that consent to experimental medicine is always invalid. The NDCT Rules themselves contemplate voluntary informed consent as the foundation of clinical trial participation. The invalidity is specific: where a practitioner represents an unproven therapy as established treatment and obtains consent on that basis, the consent is vitiated by misrepresentation of the therapy's evidential status. The ordinary consent-based bar to negligence liability is therefore unavailable, and civil and professional liability follows from the underlying duty of care.
The social justice framing the Court employs is analytically apt, if in need of calibration. The parents who sought stem cell therapies for children with ASD operated under severe informational asymmetry, caregiving desperation, no regulatory gatekeeping, and a commercial market structured to exploit both. Recognising this structural condition prevents the consent doctrine from being applied as though parties dealt at arm's length. What the Court must be careful not to do is collapse that recognition into a general paternalism that forecloses autonomous choice in genuinely experimental contexts where disclosure has been adequate and honest.
IV. The NMC Advisory of March 25, 2026
The Advisory issued by the National Medical Commission on March 25, 2026, translates the judgment's principles into an operable two-track structure. Approved indications for stem cell therapy for haematopoietic conditions, including thalassaemia major, leukaemia, and aplastic anaemia, continue under standard regulatory supervision. Unapproved indications are confined exclusively to the clinical trial pathway, subject to four conditions: no commercial charge to subjects; trial registration with the Clinical Trials Registry-India (CTRI); no payment to participants; and no-fault compensation for harm arising from trial participation.
The no-fault compensation requirement is the most notable feature. It departs from the standard tort framework requiring proof of negligence and instead adopts a quasi-strict liability approach to trial-related harm that is consistent with the Declaration of Helsinki and CIOMS Guidelines, and aligned with the compensation provisions already embedded in the NDCT Rules. Practitioners administering stem cell therapies for unapproved indications outside a registered trial are now on explicit notice. The conduct attracts criminal liability under the D&C Act, and professional sanction under the National Medical Commission Act, 2020. The Advisory functions as a signalling document; its legal authority derives from the judgment and the underlying statute, and its practical function is to eliminate any residual ambiguity about what is now required.
Yash Charitable Trust v. Union of India advances Indian medical jurisprudence in three interconnected respects. It closes the evidential gap in the negligence standard that Bolam's circularity had created. It removes the procedural escape route that the "therapy" characterisation had afforded to unlicensed stem cell administration. It establishes that the Article 21 right to informed consent is not satisfied by procedural disclosure alone; it requires that what is disclosed be grounded in an honest, evidence-based assessment of the proposed intervention.
The NMC Advisory is a cohesive framework for the regulation based on these principles. As a whole, the judgment and the Advisory create a framework for experimental biomedicine in India that is more stringent and more ethical than the one it builds on, even if the boundary disputes that remain unresolved will need to be addressed in ongoing legal battles. The long-term impact of the judgment is not on its ability to offer final answers, but to shift the inquiry from deference to evidence, from disclosure to informed decision, and from therapeutic branding to regulatory responsibility. It is a significant doctrinal shift in itself, and one that has implications which Indian courts and practitioners are only now beginning to grapple with.
Views are personal.
